Genomic Vision Achieves Major Milestone with Delivery of New High-Throughput Genome Analyzer to Quest Diagnostics

• The new analyzer is designed to enable the development of future lab-developed tests for hereditary cancers and other complex diseases based on molecular combing technology
• Goal of collaboration to extend advanced cancer testing services to patients and physicians in the United States

Genomic Vision (FR0011799907 – GV), a molecular diagnostics company specialized in the development of diagnostic tests for genetic diseases and cancers based on molecular combing, today announces the delivery of a major milestone of its strategic collaboration with Quest Diagnostics, the world’s leading provider of diagnostic information services. Genomic Vision has delivered a high-throughput genome analyzer now operational at the Quest Diagnostics clinical laboratory in San Juan Capistrano, Calif. Under terms of the collaboration, Quest Diagnostics has the right to use the instrument to create an additional laboratory-developed test for the detection of mutations in the BRCA gene, which can cause hereditary breast and ovarian cancer, and other complex diseases. The test would potentially supplement Quest’s BRCAvantage suite of BRCA test services based on next-generation sequencing.

Genomic Vision’s molecular combing technology allows the fluorescent barcoding of multiple genes involved in disease development giving each target gene a specific Genetic Morse Code. The analyzer detects and identifies signature data coming from the Genetic Morse Code. It provides a multiplexed solution to detect genomic aberrations involved in complex diseases such as cancer, muscular and neuronal development disorders.

The new analyzer was developed to increase throughput of diagnostic screening volume and reduce turnaround times, for faster results reporting.

In addition to BRCA, the collaborative terms also give Quest Diagnostics the option to use the platform to accelerate the development of lab-developed tests for other hereditary cancers, such as Lynch syndrome or hereditary nonpolyposis colorectal cancer, as well as spinal muscular atrophy.

Genomic Vision and Quest Diagnostics entered into a multi-year exclusive collaboration based on Genomic Vision's proprietary molecular combing genome-analysis technology in 2010. In 2013, Quest Diagnostics introduced the first lab-developed test, for FSHD, a debilitating myopathy, based on Genomic Vision’s technology in the United States.

“This new platform has the potential to enable us to develop new test services for improving clinical decisions involving of the care of patients at risk of developing several serious pathologies, such as hereditary breast cancer,” states Dr. Charles (Buck) Strom, Medical Director of Quest Diagnostics Nichols Institute.

“We are very pleased to offer, on time, to our US partner the new genome analyzer. This achievement was made possible due to the strong involvement of our teams and I would like to thank all our employees that took part on this important challenge. Considering the strong experience of Quest Diagnostics in developing CLIA compliant tests, I’m very confident in their ability to continue the development work that will bring to physicians and patients a clinically important alternative to current genetic technologies,” concludes Aaron Bensimon, Genomic Vision’s co-founder and Chairman.

Next financial press release

• 2014 annual revenue, on January 15, 2015 (after market)

Genomic VisionAaron BensimonCo-founder, Chairman & CEOTel.: [phone] [e-mail] Relations / Strategic CommunicationsDušan Orešanský / Emmanuel HuynhTel.: [phone] [e-mail]